Sandbox g12: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 14: | Line 14: | ||
:* '''Drugs with possible TdP risk''' | :* '''Drugs with possible TdP risk''' | ||
::* [[Atazanavir|Atazanavir (Reyataz®)]] | |||
::* [[Bedaquiline|Bedaquiline (Sirturo®)]] | ::* [[Bedaquiline|Bedaquiline (Sirturo®)]] | ||
::* [[Dihydroartemisinin | ::* [[Dihydroartemisinin+piperaquine|Dihydroartemisinin+piperaquine (Eurartesim®)]] | ||
::* [[Gatifloxacin|Gatifloxacin (Tequin®)]] | ::* [[Foscarnet|Foscarnet (Foscavir®)]] | ||
::* [[Gatifloxacin (Removed from US Market)|Gatifloxacin (Removed from US Market) (Tequin®)]] | |||
::* [[Gemifloxacin|Gemifloxacin (Factive®)]] | ::* [[Gemifloxacin|Gemifloxacin (Factive®)]] | ||
::* [[Norfloxacin|Norfloxacin (Noroxin®, Ambigram®)]] | ::* [[Norfloxacin|Norfloxacin (Noroxin®, Ambigram®)]] | ||
::* [[Ofloxacin|Ofloxacin (Floxin®)]] | ::* [[Ofloxacin|Ofloxacin (Floxin®)]] | ||
::* [[Roxithromycin|Roxithromycin (Rulide®, Xthrocin®, Roxl-150®, Roxo®, Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin®, Coroxin®)]] | ::* [[Rilpivirine|Rilpivirine (Edurant®, Complera®, Eviplera®)]] | ||
::* [[Roxithromycin (On non US Market)|Roxithromycin (On non US Market) (Rulide®, Xthrocin®, Roxl-150®, Roxo®, Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin®, Coroxin®)]] | |||
::* [[Saquinavir|Saquinavir (Invirase®(combo))]] | |||
::* [[Telavancin|Telavancin (Vibativ®)]] | ::* [[Telavancin|Telavancin (Vibativ®)]] | ||
::* [[Telithromycin|Telithromycin (Ketek®)]] | ::* [[Telithromycin|Telithromycin (Ketek®)]] | ||
Revision as of 21:48, 31 May 2015
- Risk categories for antimicrobial agents known to have an association with TdP[1]
- Drugs with known TdP risk
- Azithromycin (Zithromax®, Zmax®)
- Chloroquine (Aralen®)
- Ciprofloxacin (Cipro®, Cipro-XR®, Neofloxin®)
- Clarithromycin (Biaxin®, Prevpac®)
- Erythromycin (E.E.S.®, Robimycin®, EMycin®, Erymax®, Ery-Tab®, Eryc Ranbaxy®, Erypar®, Eryped®, Erythrocin Stearate Filmtab®, Erythrocot®, E-Base®, Erythroped®, Ilosone®, MY-E®, Pediamycin®, Zineryt®, Abboticin®, Abboticin-ES®, Erycin®, PCE Dispertab®, Stiemycine®, Acnasol®, Tiloryth®)
- Fluconazole (Diflucan®, Trican®)
- Halofantrine (Halfan®)
- Levofloxacin (Levaquin®, Tavanic®)
- Moxifloxacin (Avelox®, Avalox®, Avelon®)
- Pentamidine (Pentam®)
- Sparfloxacin (Removed from US Market) (Zagam®)
- Drugs with possible TdP risk
- Atazanavir (Reyataz®)
- Bedaquiline (Sirturo®)
- Dihydroartemisinin+piperaquine (Eurartesim®)
- Foscarnet (Foscavir®)
- Gatifloxacin (Removed from US Market) (Tequin®)
- Gemifloxacin (Factive®)
- Norfloxacin (Noroxin®, Ambigram®)
- Ofloxacin (Floxin®)
- Rilpivirine (Edurant®, Complera®, Eviplera®)
- Roxithromycin (On non US Market) (Rulide®, Xthrocin®, Roxl-150®, Roxo®, Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin®, Coroxin®)
- Saquinavir (Invirase®(combo))
- Telavancin (Vibativ®)
- Telithromycin (Ketek®)
- Drugs with conditional TdP risk
- Amantadine (Symmetrel®, Symadine®)
- Hydroxychloroquine (Plaquenil®, Quineprox®)
- Itraconazole (Sporanox®, Onmel®)
- Ketoconazole (Nizoral®, Sebizole®, Ketomed®, Keton®)
- Metronidazole (Flagyl® and many others)
- Nelfinavir (Viracept®)
- Posaconazole (Noxafil®, Posamol®)
- Quinine sulfate (Qualaquin®)
- Ritonavir (Norvir®)
- Telaprevir (Incivek®, Incivo®)
- Voriconazole (VFend®)
- Drugs to be avoided by congenital Long QT
- Torsades de pointes risk stratification schedules for antimicrobial agents[2]
- Schedule I (Highest TdP risk, potent IKr blockers, TdP risk >1%)
- Not available
- Schedule II (Significant risk for TdP, particularly when coadministered with CYP inhibitors, relatively potent IKr blockade)
- Not available
- Schedule III (Risk for TdP is described, IKr blockade, particularly when coadministered with CYP inhibitors)
- Schedule IV (Minimal risk for TdP, case reports of TdP, mild IKr blockade, may have CYP interactions)
- Schedule V (Questionable/minimal risk for QT interval prolongation/TdP)